Literature DB >> 17950310

Pathogenic mechanisms of pulmonary arterial hypertension.

Stephen Y Chan1, Joseph Loscalzo.   

Abstract

Pulmonary arterial hypertension (PAH) is a complex disease that causes significant morbidity and mortality and is clinically characterized by an increase in pulmonary vascular resistance. The histopathology is marked by vascular proliferation/fibrosis, remodeling, and vessel obstruction. Development of PAH involves the complex interaction of multiple vascular effectors at all anatomic levels of the arterial wall. Subsequent vasoconstriction, thrombosis, and inflammation ensue, leading to vessel wall remodeling and cellular hyperproliferation as the hallmarks of severe disease. These processes are influenced by genetic predisposition as well as diverse endogenous and exogenous stimuli. Recent studies have provided a glimpse at certain molecular pathways that contribute to pathogenesis; these have led to the identification of attractive targets for therapeutic intervention. We will review our current understanding of the mechanistic underpinnings of the genetic and exogenous/acquired triggers of PAH. The resulting imbalance of vascular effectors provoking pathogenic vascular changes will also be discussed, with an emphasis on common and overarching regulatory pathways that may relate to the primary triggers of disease. The current conceptual framework should allow for future studies to refine our understanding of the molecular pathogenesis of PAH and improve the therapeutic regimen for this disease.

Entities:  

Mesh:

Year:  2007        PMID: 17950310      PMCID: PMC2234575          DOI: 10.1016/j.yjmcc.2007.09.006

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  235 in total

1.  Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.

Authors:  David Launay; Luc Mouthon; Eric Hachulla; Christian Pagnoux; Pascal de Groote; Martine Remy-Jardin; Regis Matran; Marc Lambert; Viviane Queyrel; Sandrine Morell-Dubois; Loic Guillevin; Pierre-Yves Hatron
Journal:  J Rheumatol       Date:  2007-04-15       Impact factor: 4.666

2.  Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.

Authors:  M Sean McMurtry; Rohit Moudgil; Kyoko Hashimoto; Sandra Bonnet; Evangelos D Michelakis; Stephen L Archer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-01       Impact factor: 5.464

3.  Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.

Authors:  Ralph Theo Schermuly; Soni Savai Pullamsetti; Grazyna Kwapiszewska; Rio Dumitrascu; Xia Tian; Norbert Weissmann; Hossein Ardeschir Ghofrani; Christina Kaulen; Torsten Dunkern; Christian Schudt; Robert Voswinckel; Jiang Zhou; Arun Samidurai; Walter Klepetko; Renate Paddenberg; Wolfgang Kummer; Werner Seeger; Friedrich Grimminger
Journal:  Circulation       Date:  2007-04-16       Impact factor: 29.690

4.  Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.

Authors:  Georg Hansmann; Roger A Wagner; Stefan Schellong; Vinicio A de Jesus Perez; Takashi Urashima; Lingli Wang; Ahmad Y Sheikh; Renée S Suen; Duncan J Stewart; Marlene Rabinovitch
Journal:  Circulation       Date:  2007-03-05       Impact factor: 29.690

5.  Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.

Authors:  Lewis L Hsu; Hunter C Champion; Sally A Campbell-Lee; Trinity J Bivalacqua; Elizabeth A Manci; Bhalchandra A Diwan; Daniel M Schimel; Audrey E Cochard; Xunde Wang; Alan N Schechter; Constance T Noguchi; Mark T Gladwin
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  Right ventricular cardiac dysfunction in beta-thalassemia major.

Authors:  A Koren; I Garty; D Antonelli; E Katzuni
Journal:  Am J Dis Child       Date:  1987-01

7.  Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction.

Authors:  P M Steele; V Fuster; M Cohen; D G Ritter; D C McGoon
Journal:  Circulation       Date:  1987-11       Impact factor: 29.690

8.  Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension.

Authors:  M N Gillespie; S E Goldblum; D A Cohen; C J McClain
Journal:  Proc Soc Exp Biol Med       Date:  1988-01

9.  VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF).

Authors:  C P Cox; J Linden; S I Said
Journal:  Peptides       Date:  1984 Mar-Apr       Impact factor: 3.750

10.  Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Rory E Morty; Bozena Nejman; Grazyna Kwapiszewska; Matthias Hecker; Anka Zakrzewicz; Fotini M Kouri; Dorothea M Peters; Rio Dumitrascu; Werner Seeger; Petra Knaus; Ralph T Schermuly; Oliver Eickelberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-03-08       Impact factor: 8.311

View more
  101 in total

Review 1.  Cardiovascular genetic medicine: evolving concepts, rationale, and implementation.

Authors:  Ray E Hershberger
Journal:  J Cardiovasc Transl Res       Date:  2008-05-20       Impact factor: 4.132

2.  Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.

Authors:  Thomas Bertero; Katherine A Cottrill; Yu Lu; Christina M Haeger; Paul Dieffenbach; Sofia Annis; Andrew Hale; Balkrishen Bhat; Vivek Kaimal; Ying-Yi Zhang; Brian B Graham; Rahul Kumar; Rajan Saggar; Rajeev Saggar; W Dean Wallace; David J Ross; Stephen M Black; Sohrab Fratz; Jeffrey R Fineman; Sara O Vargas; Kathleen J Haley; Aaron B Waxman; B Nelson Chau; Laura E Fredenburgh; Stephen Y Chan
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

3.  Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Authors:  Neil J Kelly; Josiah E Radder; Jeffrey J Baust; Christine L Burton; Yen-Chun Lai; Karin C Potoka; Brittani A Agostini; John P Wood; Timothy N Bachman; Rebecca R Vanderpool; Nadine Dandachi; Adriana S Leme; Alyssa D Gregory; Alison Morris; Ana L Mora; Mark T Gladwin; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

Review 4.  Epigenetics: novel mechanism of pulmonary hypertension.

Authors:  Jing-bin Huang; Jian Liang; Xiao-fang Zhao; Wen-sen Wu; Fu Zhang
Journal:  Lung       Date:  2013-09-20       Impact factor: 2.584

5.  Diverse forms of pulmonary hypertension remodel the arterial tree to a high shear phenotype.

Authors:  Roblee P Allen; Edward S Schelegle; Stephen H Bennett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

Review 6.  Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.

Authors:  Dorrin Zarrin Khat; Mansoor Husain
Journal:  Curr Diab Rep       Date:  2018-06-09       Impact factor: 4.810

Review 7.  Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis.

Authors:  Jing-bin Huang; Ying-long Liu; Pei-wu Sun; Xiao-dong Lv; Kong Bo; Xiang-ming Fan
Journal:  Lung       Date:  2010-03-06       Impact factor: 2.584

Review 8.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

9.  Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension.

Authors:  Angela Ghatnekar; Izabela Chrobak; Charlie Reese; Lukasz Stawski; Francesca Seta; Elaine Wirrig; Jesus Paez-Cortez; Margaret Markiewicz; Yoshihide Asano; Russell Harley; Richard Silver; Carol Feghali-Bostwick; Maria Trojanowska
Journal:  Am J Pathol       Date:  2013-04-11       Impact factor: 4.307

Review 10.  Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension.

Authors:  Patrick Crosswhite; Zhongjie Sun
Journal:  J Hypertens       Date:  2010-02       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.